NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer
Summary
PD-1/PD-L1-blockade immunotherapies have limited efficacy in the treatment of muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma. Here, we show that KLRC1 (NKG2A) expression associates with improved survival and responsiveness to PD-L1 blockade immunotherapy in CD8Ahigh bladder tumors. The loss of antigen presentation is a common mechanism for tumor escape in bladder cancer. NKG2A+ CD8 T cells are able to circumvent HLA-ABC loss through TCR-independent cytotoxicity, which is partly mediated by DNAM-1. In bladder tumors, NKG2A is acquired on a subset of PD-1+ CD8 T cells, alongside stronger tissue-residency memory features, TCR-independent cytotoxicity and evidence of recent proliferation. HLA-E is low but variably expressed on bladder tumors. When expressed, NKG2A+ CD8 T cell anti-tumor responses to HLA-ABC-deficient tumors are inhibited and partly restored upon NKG2A blockade. Overall, our study identifies an alternative path for CD8 T cell exhaustion, that is mediated by NKG2A upregulation and TCR-independent cytotoxicity.
Competing Interest Statement
L.W., R.P.S., and J.Z. are employees of Sema4. A.H. receives research funds from Zumutor Biologics; and is on the advisory boards of HTG Molecular Diagnostics, Immunorizon, and Takeda. N.B. is an extramural member of the Parker Institute for Cancer Immunotherapy; receives research funds from Regeneron, Harbor Biomedical, DC Prime, and Dragonfly Therapeutics; and is on the advisory boards of Neon Therapeutics, Novartis, Avidea, Boehringer Ingelheim, Rome Therapeutics, Rubius Therapeutics, Roswell Park Comprehensive Cancer Center, BreakBio, Carisma Therapeutics, CureVac, Genotwin, BioNTech, Gilead Therapeutics, Tempest Therapeutics, and the Cancer Research Institute.
Footnotes
↵‡ Lead contact
Subject Area
- Biochemistry (11699)
- Bioengineering (8715)
- Bioinformatics (29119)
- Biophysics (14927)
- Cancer Biology (12047)
- Cell Biology (17347)
- Clinical Trials (138)
- Developmental Biology (9405)
- Ecology (14138)
- Epidemiology (2067)
- Evolutionary Biology (18261)
- Genetics (12216)
- Genomics (16760)
- Immunology (11839)
- Microbiology (27996)
- Molecular Biology (11549)
- Neuroscience (60781)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3228)
- Physiology (4937)
- Plant Biology (10382)
- Synthetic Biology (2876)
- Systems Biology (7332)
- Zoology (1642)